Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer
HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.
- HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.
- ValoTx's CEO, Paul Higham, said, "I am delighted to welcome Dr Hemanshu Shah as our CBO.
- He'll be making the most of the substantial business development opportunities represented by our unique cancer and infectious disease immunotherapy platforms.
- Dr Hemanshu Shah has a deep heritage in business development and corporate development transactions, coupled with US and global marketing experience.